Inovio Pharmaceuticals shares climbed around +20% Tuesday, following the company’s announcement about its progress on developing a coronavirus vaccine.
The biotech company revealed that it has sped its timeline for developing the vaccine, and is planning human trials beginning April.
Inovio plans to start human clinical trials in the U.S. in April, followed by trials in China and South Korea.
The company intends to implement 1 million doses by the end of the year.
But J. Joseph Kim, president and CEO, added that Inovio would need to expand resources to make enough doses to help protect Americans from Covid-19 as well as to lead global efforts to combat this virus.